Biblio

Author Title [ Type

] Year

Filters: Author is Shimoni, Avichai [Clear All Filters]

Journal Article

Resnick IB, Barkats C, Shapira MY, Stepensky P, Bloom AI, Shimoni A, Mankuta D, Varda-Bloom N, Rheingold L, Yeshurun M, et al. Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). Am J Blood Res. 2013;3(3):225-38.

Yerushalmi Y, Shem-Tov N, Danylesko I, Canaani J, Avigdor A, Yerushalmi R, Nagler A, Shimoni A. Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/ myelodysplastic syndromes after a first transplantation. Haematologica. 2022.

Nagler A, Labopin M, Dholaria B, Finke J, Brecht A, Schanz U, Niittyvuopio R, Neubauer A, Bornhäuser M, Santarone S, et al. Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol. 2019.

Michael M, Shimoni A, Nagler A. Regulatory T Cells in Allogeneic Stem Cell Transplantation. Clin Dev Immunol. 2013;2013:608951.

Shimoni A, Zwas STzila. Radioimmunotherapy and Autologous Stem-Cell Transplantation in the Treatment of B-Cell Non-Hodgkin Lymphoma. Semin Nucl Med. 2016;46(2):119-125.

van Gorkom G, Finel H, Giebel S, Pohlreich D, Shimoni A, Ringhoffer M, Sucak G, Schaap N, Dreger P, Sureda A, et al. Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas. J Clin Apher. 2016.

Kedmi M, Shouval R, Fried S, Bomze D, Fein J, Cohen Z, Danilesko I, Shem-Tov N, Yerushalmi R, Jacoby E, et al. Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B cell lymphoma. Transplant Cell Ther. 2022.

Davidov Y, Shem-Tov N, Yerushalmi R, Hod T, Ben-Ari Z, Nagler A, Shimoni A, Danylesko I. Liver stiffness measurements predict Sinusoidal Obstructive Syndrome after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2024.

Shimoni A, Labopin M, Lorentino F, van Lint MTeresa, Koc Y, Gulbas Z, Tischer J, Bruno B, Blaise D, Pioltelli P, et al. Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide. Leukemia. 2018.

Youngster I, Eshel A, Geva M, Danylesko I, Henig I, Zuckerman T, Fried S, Yerushalmi R, Shem-Tov N, Fein JA, et al. Fecal microbiota transplantation in capsules for the treatment of steroid refractory and steroid dependent acute graft vs. host disease: a pilot study. Bone Marrow Transplant. 2024.

Danylesko I, Canaani J, Shimoni A, Fein J, Shem-Tov N, Yerushalmi R, Shouval R, Nagler A. Complete Remission with Incomplete Blood Count Recovery Is a Strong Predictor of Nonrelapse Mortality in Acute Myeloid Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Acta Haematol. 2021:1-7.

Shimoni A, Labopin M, Savani B, Byrne M, Volin L, Finke J, Niederwieser D, Ehninger G, Blaise D, Beelen D, et al. Comparable Long-Term Outcome after Allogeneic Stem-Cell Transplantation from Sibling and Matched Unrelated Donors in AML Patients Older than 50 years. A Report on Behalf of the ALWP of EBMT. Biol Blood Marrow Transplant. 2019.

Shem-Tov N, Labopin M, Moukhtari L, Ciceri F, Esteve J, Giebel S, Gorin N-C, Schmid C, Shimoni A, Nagler A, et al. Chemotherapy Dose Adjustment for Obese Patients Undergoing Hematopoietic Stem Cell Transplantation: A Survey on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Oncologist. 2014.

Mei M, Wondergem MJ, Palmer JM, Shimoni A, Hasenkamp J, Tsai N-C, Simpson J, Nademanee A, Raubitschek A, Forman SJ, et al. Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen. Biol Blood Marrow Transplant. 2014.

Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, Volin L, Poire X, Aljurf M, Masszi T, et al. Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan Plus Cyclophosphamide (Cy) Versus Total-Body Irradiation Plus Cy As Conditioning Regimen--A Report From the Acute Leukemia Worki. J Clin Oncol. 2013.

Berning P, Schmitz N, Ngoya M, Finel H, Boumendil A, Wang F, Huang X-J, Hermine O, Philippe L, Couronné L, et al. Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis. Leukemia. 2023.